Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives $6.25 Consensus Price Target from Analysts

Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) have earned an average recommendation of “Buy” from the six analysts that are presently covering the stock, MarketBeat reports. Six investment analysts have rated the stock with a buy rating. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $6.25.

Several analysts recently commented on TNYA shares. Wall Street Zen upgraded Tenaya Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 9th. HC Wainwright reiterated a “buy” rating and issued a $5.00 target price on shares of Tenaya Therapeutics in a report on Tuesday, September 2nd. Finally, Chardan Capital reiterated a “buy” rating and issued a $9.00 target price on shares of Tenaya Therapeutics in a report on Thursday, August 7th.

Tenaya Therapeutics Price Performance

Tenaya Therapeutics stock opened at $1.41 on Friday. Tenaya Therapeutics has a 12-month low of $0.36 and a 12-month high of $4.01. The business’s 50-day moving average price is $1.01 and its two-hundred day moving average price is $0.71. The stock has a market cap of $229.80 million, a PE ratio of -1.47 and a beta of 3.06.

Tenaya Therapeutics (NASDAQ:TNYA) last released its earnings results on Wednesday, August 6th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.06. As a group, analysts expect that Tenaya Therapeutics will post -1.35 earnings per share for the current year.

Hedge Funds Weigh In On Tenaya Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Woodline Partners LP lifted its stake in Tenaya Therapeutics by 30,563.2% in the first quarter. Woodline Partners LP now owns 5,916,167 shares of the company’s stock valued at $3,373,000 after buying an additional 5,896,873 shares during the period. AQR Capital Management LLC acquired a new position in shares of Tenaya Therapeutics during the first quarter worth approximately $442,000. Northern Trust Corp raised its position in shares of Tenaya Therapeutics by 6.2% during the fourth quarter. Northern Trust Corp now owns 472,479 shares of the company’s stock worth $676,000 after purchasing an additional 27,632 shares during the period. Marex Group plc purchased a new stake in Tenaya Therapeutics in the 2nd quarter valued at $252,000. Finally, Jane Street Group LLC raised its position in Tenaya Therapeutics by 1,958.7% in the 2nd quarter. Jane Street Group LLC now owns 376,068 shares of the company’s stock valued at $230,000 after buying an additional 357,801 shares during the last quarter. 90.54% of the stock is owned by institutional investors and hedge funds.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.